参考文献/References:
[1] Maggioni AP, Orso F, Calabria S, et al. The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database[J]. Eur J Heart Fail, 2016,18(4):402-410.
[2] 谭漪扬, 周建中. 慢性心力衰竭治疗新进展——LCZ696![J]. 心血管病学进展, 2016,37(1):42-45.
[3] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines[J]. Circulation, 2013,128(16):1810-1852.
[4] Kobalava Z, Kotovskaya Y, Averkov O, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction[J]. Cardiovasc Ther, 2016,34(4): 191-198.
[5] Mcmurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004.
[6] Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure[J]. Heart Fail Rev, 2019,24(2):167-176.
[7] Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial[J]. Eur J Heart Fail, 2019,21(3):337-341.
[8] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8): 891-975.
[9] Writing Committee Members,ACC/AHA Task Force Members. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 accf/aha guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america[J]. J Card Fail, 2016, 22(9): 659-669.
[10] 中华医学会心血管病学分会心力衰竭学组 中国医师协会心力衰竭专业委员会 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018,46(10):760-789.
[11] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019,380(6):539-548.
[12] Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure[J]. J Am Coll Cardiol, 2016,68(22):2425-2436.
[13] Simpson J, Benson L, Jhund PS, et al. "Real World" eligibility for sacubitril/valsartan in unselected heart failure patients: data from the swedish heart failure registry[J]. Cardiovasc Drugs Ther, 2019,33(3):315-322.
[14] Bastien N, Haddad H, Bergeron S, et al. THE parasail study: patient reported outcomes from the canadian real world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction[J]. Can J Cardiol, 2017,33(10):S162-162S163.
[15] Vicent L, Esteban-Fernández A, Gómez-Bueno M, et al. Sacubitril/valsartan in daily clinical practice: data from a prospective registry[J]. J Cardiovasc Pharmacol, 2019,73(2):118-124.
[16] Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany[J]. Eur J Heart Fail, 2019,21(5):588-597.
[17] Martens P, Lambeets S, Lau CW, et al. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions[J]. Acta Cardiol, 2019,74(2):115-122.
[18] Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial[J]. Circ Heart Fail, 2016,9(1):e002560.
[19] Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol, 2017,5(5):333-340.
[20] B?hm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF[J]. Eur Heart J, 2017,38(15):1132-1143.
[21] Senni M, Jjv MM, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study[J]. Eur J Heart Fail, 2018,20(3):491-500.
[22] Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial[J]. Eur J Heart Fail, 2016,18(10): 1228-1234.
[23] Antol DD, Casebeer AW, DeClue RW, et al. An early view of real-world patient response to sacubitril/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction[J]. Adv Ther, 2018,35(6):785-795.
[24] de Vecchis R, Ariano C, di Biase G, et al. In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : a?retrospective cohort study[J]. Herz, 2018, 44 (7): 651-658
相似文献/References:
[1]王文艳 李晓东 伍鑫 袁小媚 孔洪.间断重复使用左西孟旦在不同肾小球滤过率的进展期心力衰竭中的作用比较[J].心血管病学进展,2020,(1):98.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.026]
WANG WenyanLI Xiaodong,WU Xin,YUAN Xiaomei,et al.Effect of Intermediate Repetitive Levosimendan Treatment in Patients with Advanced Heart Failure of Different eGFR[J].Advances in Cardiovascular Diseases,2020,(9):98.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.026]
[2]潘东 罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
PAN DongLUO Yong.Sacubitril/valsartan in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
[3]费美莹 姜东炬.心力衰竭药物沙库巴曲缬沙坦的研究进展[J].心血管病学进展,2020,(2):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
FEI Meiying J IANG Dongju.Heart Failure Drug Sacubitril Valsartan[J].Advances in Cardiovascular Diseases,2020,(9):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
[4]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
[5]王晓旭,羊镇宇.沙库巴曲缬沙坦在血压治疗中的研究进展[J].心血管病学进展,2021,(2):138.[doi:10.16806/j.cnki.issn.1004-3934.20.02.011]
WANG Xiaoxu,YANG Zhenyu.Advances in the Study of LCZ696 in Hypertension[J].Advances in Cardiovascular Diseases,2021,(9):138.[doi:10.16806/j.cnki.issn.1004-3934.20.02.011]
[6]王毅 佘强.射血分数降低性心力衰竭的药物进展[J].心血管病学进展,2021,(11):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG Yi,SHE Qiang.Advancement of Drug Therapy in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(9):990.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[7]贾晓艳 安晋阳 彭可玲 刘永铭.可溶性鸟苷酸环化酶激动剂治疗射血分数保留性心力衰竭的研究进展[J].心血管病学进展,2022,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
JIA Xiaoyan,AN Jinyang,PENG Keling,et al.Soluble Guanylate Cyclase Stimulators in the Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
[8]李春燕 汪祥勇 刘剑雄.Omecamtiv Mecarbil在射血分数降低性心力衰竭中的临床研究进展[J].心血管病学进展,2023,(3):243.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.012]
LI ChunyanWANG XiangyongLIU Jianxiong.Clinical Study of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction[J].Advances in Cardiovascular Diseases,2023,(9):243.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.012]
[9]穆耶赛尔·玉苏普 芦颜美 汤宝鹏.沙库巴曲缬沙坦对心力衰竭患者认知功能的影响[J].心血管病学进展,2023,(8):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]
Muyassar·Yusup,LU Yanmei,TANG Baopeng.Effect of Sacubritil/Valsartan on Cognitive Function in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2023,(9):709.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.009]